SINTX Technologies — Q3 2026 Earnings Summary

Financial Performance

• Preliminary, unaudited third-quarter revenue reached $2.2 million, exceeding the high-end guidance range of $0.9 million to $1.1 million.
• Revenue grew approximately 380% from the second quarter of 2026.
• Third-quarter revenue was over ten times the amount recorded in the prior year quarter.
• Approximately $2.1 million of the revenue was derived from product sales.
• The company expects narrower losses in the third quarter compared to previous quarters due to increased sales.
• Revenue figures are preliminary and subject to adjustment following the completion of quarter-end financial close procedures.

Guidance and Future Outlook

• The company reiterates its fourth-quarter revenue guidance range previously provided during the last quarterly earnings call.
• Management anticipates continued focus on reliable delivery, repeat business, and disciplined manufacturing costs.
• The company is transitioning toward a more diversified commercial-stage advanced materials company.

Business Segments and Product Lines

• Industrial ceramics sales to aerospace subsidiaries of Fortune 500 companies accounted for the majority of third-quarter revenue.
• Shipments began against over $3.2 million in contract manufacturing purchase orders announced in June, converting a portion into recognized revenue.
• The company expanded commercial infrastructure for its silicon nitride orthopedic portfolio, including the FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System.
• Development continues on the SiNERGY™ technology platform across biocomposite and 3D printing capabilities.
• Antimicrobial textiles are being developed as part of the platform for orthopedic, spine, craniofacial, dental, suture, and wound-management applications.

Market and Competitive Landscape

• The company leverages U.S.-based manufacturing operations to convert industrial customer orders into revenue at scale.
• Strategic industry relationships and a patent portfolio support the company's commercialization efforts.

Risks and Challenges

• Final reported revenue may differ materially from preliminary results due to adjustments during the financial closing process.
• Warrant exercise proceeds are not assured; holders may fail to exercise warrants in a timely manner, causing them to expire.
• Potential risks include the inability to successfully develop and commercialize products, obtain regulatory approvals, achieve market acceptance, protect intellectual property, manufacture at commercial scale, or satisfy customer orders on schedule.
• The company may receive less proceeds than anticipated or no proceeds at all from the warrant exercise.

Management Commentary and Tone

• Eric Olson, Chairman and CEO, expressed pleasure with the results of efforts to improve manufacturing and operational efficiency.
• Management highlighted the ability to turn industrial customer orders into revenue at scale as a key demonstration of capability.
• The tone reflects confidence in the execution of the transition to a diversified commercial-stage company.

Other Key Points

• The company intends to deliver a Call Notice to holders of Class B Warrants to purchase an aggregate of approximately 1.88 million shares of Common Stock.
• The third-quarter product revenue of $2.1 million surpassed the Call Right trigger of at least $2.0 million in product revenue during a fiscal quarter.
• If the warrants are fully exercised, cash proceeds could provide up to $4.0 million in additional capital.
• The per share exercise price will be the closing price of the Company's Common Stock at the close of the trading day immediately preceding the date of the Call Notice.